Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease
Nurulamin M Noor, Paula Sousa, Dominik Bettenworth, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 7, pp. 1031-1045
Open Access | Times Cited: 18

Showing 18 citing articles:

Biological therapy for inflammatory bowel disease: cyclical rather than lifelong treatment?
Christian P. Selinger, Konstantina Rosiou, Marco Vincenzo Lenti
BMJ Open Gastroenterology (2024) Vol. 11, Iss. 1, pp. e001225-e001225
Open Access | Times Cited: 8
Progressing advanced therapies for inflammatory bowel disease: Current status including dual biologic therapy and discontinuation of biologics
Kazuo Yashima, Hiroki Kurumi, Naoyuki Yamaguchi, et al.
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU
María José Casanova, Cristina Rubín de Célix, Sabino Riestra, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU
Javier P. Gisbert, María G. Donday, Sabino Riestra, et al.
Gut (2024), pp. gutjnl-333385
Closed Access | Times Cited: 3
De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review
Javier P. Gisbert, María Chaparro
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 4, pp. 642-658
Closed Access | Times Cited: 7
Managing Ulcerative Colitis and Crohn’s Disease: Should the Target Be Endoscopy, Histology, or Both?
Fernando Magro, María Manuela Estevinho, André Valois
Journal of the Canadian Association of Gastroenterology (2023) Vol. 7, Iss. 1, pp. 46-58
Open Access | Times Cited: 5
Influential factors on disease activity in Crohn’s disease and their Roc curve evaluation: a cross-sectional study
Jing Wang, Shuping Tong, Bingqing Lu
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn’s disease stopping infliximab
Nicolas Pierre, Vân Anh Huynh‐Thu, Dominique Baiwir, et al.
Gut (2024), pp. gutjnl-332648
Closed Access | Times Cited: 1
Common Mistakes in Managing Patients with Inflammatory Bowel Disease
Javier P. Gisbert, María Chaparro
(2024)
Open Access | Times Cited: 1
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab
Paula Sousa, Marta Patita, Bruno Arroja, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 5, pp. 737-743
Open Access | Times Cited: 2
Withdrawal of Anti-Tumour Necrosis Factor in Inflammatory Bowel Disease Patients in Remission: A Randomised Placebo-Controlled Clinical Trial of GETECCU
Javier P. Gisbert, María García-Donday, Sabino Riestra, et al.
(2023)
Closed Access | Times Cited: 1
De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice
Álex Arenas, María José Moreta, Íngrid Ordás, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 7, pp. 673-682
Closed Access
Common Mistakes in Managing Patients with Inflammatory Bowel Disease
Javier P. Gisbert, María Chaparro
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4795-4795
Open Access
Interrupting inflammatory bowel disease therapy: why, who, when and how to consider medication holidays
Joëlle St‐Pierre, Asher Shafrir, David T. Rubin
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 10, pp. 587-596
Closed Access
Trajectories of adherence to intravenous biological treatment in patients with inflammatory bowel disease: a longitudinal analysis
Xiuli Dong, Suyan Zhu, Yiyi Jin, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Biologics in the management of pediatric inflammatory bowel disease: When and what to choose
Arghya Samanta, Anshu Srivastava
World Journal of Clinical Pediatrics (2024) Vol. 14, Iss. 1
Closed Access
De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice
Álex Arenas, María José Moreta, Íngrid Ordás, et al.
Gastroenterología y Hepatología (2023) Vol. 47, Iss. 7, pp. 673-682
Closed Access
Investigation of Ogikenchuto (TJ‐98) for intestinal fibrosis using a mouse model of dextran sulfate sodium‐induced colitis
Shunsuke Watanabe, Mikihiro Inoue, Atsuki Naoe, et al.
Traditional & Kampo Medicine (2023) Vol. 11, Iss. 1, pp. 3-12
Open Access
Page 1

Scroll to top